BR112016028672A2 - análogos de ribosídeo de nicotinamida e composições farmacêuticas e usos do mesmo - Google Patents

análogos de ribosídeo de nicotinamida e composições farmacêuticas e usos do mesmo

Info

Publication number
BR112016028672A2
BR112016028672A2 BR112016028672A BR112016028672A BR112016028672A2 BR 112016028672 A2 BR112016028672 A2 BR 112016028672A2 BR 112016028672 A BR112016028672 A BR 112016028672A BR 112016028672 A BR112016028672 A BR 112016028672A BR 112016028672 A2 BR112016028672 A2 BR 112016028672A2
Authority
BR
Brazil
Prior art keywords
nicotinamide riboside
pharmaceutical compositions
disorder
treat
ester
Prior art date
Application number
BR112016028672A
Other languages
English (en)
Inventor
Szczepankiewicz Bruce
PREUGSCHAT Frank
Koppetsch Karsten
B Perni Robert
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of BR112016028672A2 publication Critical patent/BR112016028672A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/004—Aftersun preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/048—Pyridine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/522—Antioxidants; Radical scavengers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Birds (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

resumo ?análogos de ribosídeo de nicotinamida e composições farmacêuticas e usos do mesmo? são aqui fornecidos análogos de éster e carbonato estereoisomericamente puros de ribosídeo de nicotinamida e hidreto de ribosídeo de nicotinamida, e composições farmacêuticas e suas utilizações. os análogos de éster e carbonato estereoisomericamente puros de ribosídeo de nicotinamida e hidreto de ribosídeo de nicotinamida podem ser utilizados para tratar uma doença ou distúrbio que se beneficiaria com níveis aumentados de nad incluindo uma doença ou distúrbio mitocondrial, resistência à insulina, uma síndrome metabólica, diabetes, obesidade, para aumentar sensibilidade à insulina num indivíduo, ou para tratar ou prevenir uma condição da pele.
BR112016028672A 2014-06-06 2015-06-05 análogos de ribosídeo de nicotinamida e composições farmacêuticas e usos do mesmo BR112016028672A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462008707P 2014-06-06 2014-06-06
PCT/IB2015/054281 WO2015186114A1 (en) 2014-06-06 2015-06-05 Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof

Publications (1)

Publication Number Publication Date
BR112016028672A2 true BR112016028672A2 (pt) 2017-08-22

Family

ID=53398163

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016028672A BR112016028672A2 (pt) 2014-06-06 2015-06-05 análogos de ribosídeo de nicotinamida e composições farmacêuticas e usos do mesmo

Country Status (11)

Country Link
US (1) US10485814B2 (pt)
EP (1) EP3152220A1 (pt)
JP (1) JP6559713B2 (pt)
KR (1) KR20170008320A (pt)
CN (1) CN106715455A (pt)
AU (1) AU2015270090A1 (pt)
BR (1) BR112016028672A2 (pt)
CA (1) CA2951287A1 (pt)
MX (1) MX2016016071A (pt)
RU (1) RU2016149767A (pt)
WO (1) WO2015186114A1 (pt)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106715454B (zh) 2014-07-24 2020-06-16 格雷斯公司 烟酰胺核苷的结晶形式
MX2017011851A (es) * 2015-03-16 2018-04-11 Chromadex Inc Composiciones de acido nicotinico ribosido o de nicotinamida ribosido, derivados reducidos de los mismos, y su uso.
US20160317418A1 (en) * 2015-05-01 2016-11-03 The Procter & Gamble Company Method of improving the appearance of skin and compositions therefor
US11426398B2 (en) 2015-06-10 2022-08-30 Elysium Health, Inc. Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders
US11013678B2 (en) 2015-06-29 2021-05-25 The Procter & Gamble Company Multi-component skin care product
US10392414B2 (en) 2015-07-15 2019-08-27 Cornell University Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives
EP3331894B1 (en) 2015-08-05 2021-02-17 Metro International Biotech, LLC Nicotinamide mononucleotide derivatives and their uses
ES2812456T3 (es) * 2015-12-21 2021-03-17 Showa Denko Kk Derivado de mononucleótido de nicotinamida y sal del mismo, método para producir el mismo, agente tópico, cosmético y aditivo alimentario
EP3236928B1 (en) 2016-01-11 2020-12-09 The Procter and Gamble Company Method of treating a skin condition and compositions therefor
EP3429354A4 (en) 2016-03-16 2020-03-25 Chromadex Inc. B-VITAMIN AND AMINO ACID CONJUGATES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, DERIVATIVES THEREOF AND METHOD FOR THE PRODUCTION THEREOF
NZ747693A (en) 2016-04-20 2023-07-28 Chromadex Inc Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as nad+increasing precursors
EP4252775A3 (en) 2016-07-15 2023-12-20 H2 Water Technologies Ltd Composition for producing hydrogen rich water
GB2553001A (en) * 2016-08-19 2018-02-21 The Queen's Univ Of Belfast Lactone intermediates of nicotinamide riboside and nicotinate riboside
US9975915B1 (en) 2016-11-11 2018-05-22 The Queen's University Of Belfast Crystalline forms of nicotinoyl ribosides, modified derivatives thereof, and phosphorylated analogs thereof, and methods of preparation thereof
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
CA3044814A1 (en) 2016-11-29 2018-06-07 Charles M. Brenner Use of nad precursors for improving maternal health and/or offspring health
US20200121704A1 (en) * 2017-01-13 2020-04-23 The Regents Of The University Of Colorado, A Body Corporate Methods for treating hypertension and arterial stiffness
PT3606929T (pt) * 2017-04-05 2021-09-02 Univ Cornell Nucleótidos de éster de beta-nicotinato e processos de preparação dos mesmos
WO2018200357A1 (en) * 2017-04-26 2018-11-01 Elysium Health, Inc. Methods and compositions of improving fertility
US20200179441A1 (en) * 2017-04-27 2020-06-11 H2 Water Technologies Ltd. Synergistic compositions for increasing mitochondrial function and energy
US11286274B2 (en) 2017-06-19 2022-03-29 Mitopower Llc Nicotinamide riboside derivatives and their uses
JP6997222B2 (ja) 2017-06-23 2022-01-17 ザ プロクター アンド ギャンブル カンパニー 皮膚の外観を改善するための組成物及び方法
CN111601814A (zh) * 2017-10-19 2020-08-28 益力舒健康公司 Tdp-43相关疾病的预防和治疗
US20200261483A1 (en) * 2017-10-30 2020-08-20 Elysium Health, Inc. Methods and compositions for treating cystic fibrosis
US20210177875A1 (en) * 2017-12-01 2021-06-17 Elysium Health, Inc. Methods and compositions for treating childhood or teen obesity
EP3794011A1 (en) * 2018-05-15 2021-03-24 Jumpstart Fertility Pty Ltd Amino acid salts of nicotinic acid mononucleotide and nicotinamide mononucleotide as anti-ageing agents
CN113490675A (zh) * 2018-05-22 2021-10-08 江普斯塔特生育有限公司 作为抗衰老剂的烟酸核苷的氨基酸盐
WO2020010036A1 (en) 2018-07-03 2020-01-09 The Procter & Gamble Company Method of treating a skin condition
CN108774278A (zh) * 2018-09-10 2018-11-09 张洪喜 一种制备尼克酰胺核苷盐的方法
WO2020081361A1 (en) * 2018-10-17 2020-04-23 Imbria Pharmaceuticals, Inc. Methods of treating rheumatic diseases using trimetazidine-based compounds
EP3897666A2 (en) 2018-12-17 2021-10-27 Mitopower LLC Nicotinyl riboside compounds and their uses
CN109674808A (zh) * 2019-01-30 2019-04-26 四川大学 β-烟酰胺单核苷酸或其前体在制备延缓肺衰老药物中的用途
MX2021010043A (es) * 2019-02-21 2022-07-19 Chromadex Inc Uso de nicotinamida ribósido, ácido nicotinico ribósido, compuestos de nicotinil ribósido reducido y derivados de compuestos de nicotinil ribósido en formulaciones.
US11939348B2 (en) 2019-03-22 2024-03-26 Metro International Biotech, Llc Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide
US20220249535A1 (en) * 2019-04-05 2022-08-11 Rejuvenation Therapeutics Compositions comprising nicotinamide adenine dinucleotide-related compounds and use thereof
EP3980028A1 (en) * 2019-06-05 2022-04-13 Société des Produits Nestlé S.A. Reduced nicotinamideribosides for treating/preventing skeletal muscle disease
EP3980027A1 (en) * 2019-06-05 2022-04-13 Société des Produits Nestlé S.A. Reduced nicotinamideribosides for the treatment/prevention of liver disease
JP2022534869A (ja) * 2019-06-05 2022-08-04 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 腎疾患を治療又は予防するための還元型ニコチンアミドリボシド
US20200397807A1 (en) * 2019-06-18 2020-12-24 MitoPower, LLC Nicotinyl riboside compounds and their uses
US20220324899A1 (en) * 2019-08-14 2022-10-13 Metro International Biotech, Llc Compounds and compositions for differential modulation of nicotinamide adenine dinucleotide
FR3103702B1 (fr) * 2019-11-28 2022-02-11 Nuvamid Sa Utilisation de NMN pour la prévention et/ou le traitement de la spondylarthrite ankylosante et compositions correspondantes
CN110755432A (zh) * 2019-12-02 2020-02-07 浙江大学 烟酰胺在制备治疗手足皮肤反应制剂中的应用
FR3107897B1 (fr) * 2020-03-06 2023-05-26 Nuvamid Sa Dérivés de nicotinamide mononucléotides
US20230133114A1 (en) * 2020-03-09 2023-05-04 Societe Des Produits Nestle S.A. Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of viral and bacterial infections
EP4117677A1 (en) * 2020-03-09 2023-01-18 Société des Produits Nestlé S.A. Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of cardiovascular diseases and conditions
WO2021180741A1 (en) * 2020-03-09 2021-09-16 Société des Produits Nestlé S.A. Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of pancreatic diseases and conditions
WO2021180732A1 (en) * 2020-03-09 2021-09-16 Société des Produits Nestlé S.A. Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of neurological diseases and conditions
FR3108032B1 (fr) * 2020-03-12 2024-02-16 Nuvamid Sa Utilisation de NMN pour la prévention et/ou le traitement d’une douleur musculaire, ligamentaire ou tendineuse induite par l’activité physique et compositions correspondantes
FR3108031B1 (fr) * 2020-03-12 2024-02-16 Nuvamid Sa Utilisation de NMN pour la prévention et/ou le traitement d’une douleur dorsale et compositions correspondantes
CN111454311B (zh) 2020-04-03 2021-10-19 深圳市迪克曼科技开发有限公司 烟酰胺核糖的有机酸盐及其组合物与制备方法
EP3901160A1 (en) * 2020-04-25 2021-10-27 Nuvamid SA Nicotinamide mononucleotide and nicotinamide riboside derivatives and use thereof in the treatment of viral infections and respiratory complications, in particular caused by influenzavirus or coronavirus
EP4139322A1 (en) * 2020-04-24 2023-03-01 Nuvamid SA Nicotinamide mononucleotide and nicotinamide riboside derivatives and use thereof in the treatment of viral infections and respiratory complications, in particular caused by influenzavirus or coronavirus
WO2021231874A1 (en) * 2020-05-15 2021-11-18 Psimos, Inc Composition for growth stimulation and resistance to stress factors for plants of the cannabaceae family
CN113768946A (zh) * 2020-05-25 2021-12-10 南京帝昌医药科技有限公司 一种治疗糖尿病皮肤并发症的软膏及其制备方法
US11583488B2 (en) 2020-06-01 2023-02-21 The Procter & Gamble Company Method of improving penetration of a vitamin B3 compound into skin
US10959933B1 (en) 2020-06-01 2021-03-30 The Procter & Gamble Company Low pH skin care composition and methods of using the same
US20230255994A1 (en) * 2020-07-01 2023-08-17 Metro International Biotech, Llc Treatment of covid-19 and/or acute kidney injury
CN114053292A (zh) * 2020-07-31 2022-02-18 高志玲 烟酰胺核苷芳甲酸酯类化合物及其组合物的用途以及化合物晶型
JP2023538259A (ja) * 2020-08-07 2023-09-07 ヌバミッド エスエー 抗悪性腫瘍薬誘発毒性の処置および防止におけるニコチンアミドモノヌクレオチド誘導体およびその使用
WO2022077276A1 (zh) * 2020-10-14 2022-04-21 音芙医药科技(上海)有限公司 烟酰胺单核苷酸与发酵乳杆菌联合在制备缓解皮肤光老化制剂中的应用
CA3206030A1 (en) * 2020-12-18 2022-06-23 Nuvamid Sa Nicotinamide mononucleotide derivatives and use thereof in the treatment and prevention of a red blood cell disorder
WO2022251491A1 (en) 2021-05-27 2022-12-01 Metro International Biotech, Llc Crystalline solids of nicotinic acid mononucleotide and esters thereof and methods of making and use
CN113308436A (zh) * 2021-06-24 2021-08-27 海南赛奥干细胞生物科技有限公司 一种人类骨髓、脐带血干细胞处理试剂盒及干细胞分离方法
CN113398145B (zh) * 2021-07-02 2022-10-14 合肥康诺生物制药有限公司 含nad与氨氯地平的药物组合物及其用途
KR20240047371A (ko) * 2021-07-12 2024-04-12 싸이토키네틱스, 인코포레이티드 Cd38 조절제 및 이의 사용 방법
CA3231499A1 (en) * 2021-09-30 2023-04-06 Bing Yan Nicotinamide riboside trioleates chloride, compositions containing this compound, and methods of making and using this compound
CN115304655A (zh) * 2021-11-23 2022-11-08 中立安(北京)医药科技有限公司 烟酰胺单核苷类衍生物及其制备方法和应用
CN115232184A (zh) * 2021-12-06 2022-10-25 宁波熙健医药科技有限公司 呋喃核糖基吡啶衍生物及其药物组合物和用途
CN115400140B (zh) * 2022-01-27 2024-02-20 宁波熙健医药科技有限公司 呋喃核糖基吡啶衍生物用于预防或治疗癫痫或惊厥的用途
WO2023154844A2 (en) * 2022-02-10 2023-08-17 Workman David Henry Compositions comprising nad+ and associated methods of treatment

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2798076A (en) 1952-03-14 1957-07-02 Hoffmann La Roche 1-isonicotinyl-2-hydroxyalkylhydrazines
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US5470838A (en) * 1987-10-28 1995-11-28 Pro-Neuron, Inc. Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
DE69721339T2 (de) 1996-10-16 2004-01-22 Ribapharm, Inc., Costa Mesa Monozyklische l-nukleoside, analoga und ihre anwendungen
US6337065B1 (en) 1998-12-01 2002-01-08 University Of Kentucky Research Foundation Method for enhancing protective cellular responses to genotoxic stress in skin
US6495537B1 (en) 1998-12-01 2002-12-17 University Of Kentucky Research Foundation Method for inhibition of photocarcinogenesis or photoimmunosuppression using niacin
US6288089B1 (en) 1998-12-21 2001-09-11 Michael Zawada Use of kinase inhibitors for treating neurodegenerative diseases
JP4156841B2 (ja) 2000-04-14 2008-09-24 ナイアダイン コーポレーション ナイアシンの経皮送達用局所製剤および高脂血症の処置方法
US6689760B1 (en) 2000-07-10 2004-02-10 Enzrel Inc. Anti-mycobacterial compositions
CA2421269A1 (en) 2002-08-09 2004-02-09 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
WO2005002672A2 (en) 2003-07-01 2005-01-13 President And Fellows Of Harvard College Sirt1 modulators for manipulating cells/organism lifespan/stress response
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
US8114626B2 (en) 2004-02-10 2012-02-14 Trustees Of Dartmouth College Yeast strain and method for using the same to produce nicotinamide riboside
US20050227327A1 (en) 2004-02-10 2005-10-13 Brenner Charles M Nicotinamide riboside kinase compositions and methods for using the same
WO2005077091A2 (en) 2004-02-10 2005-08-25 Trustees Of Dartmouth College Nicotinamide riboside kinase compositions and methods for using the same
US7776326B2 (en) 2004-06-04 2010-08-17 Washington University Methods and compositions for treating neuropathies
US20060229265A1 (en) * 2005-03-30 2006-10-12 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
AU2006278396A1 (en) 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Benzimidazole derivatives as sirtuin modulators
EP3369738B1 (en) 2005-11-18 2020-05-20 Cornell Research Foundation, Inc. Method for making nicotinoyl ribosides and nicotinamide beta-riboside
US20120135091A1 (en) 2007-01-18 2012-05-31 Roth Mark B Methods and compositions for enhancing lifespan involving sirtuin-modulating compounds and chalcogenides
CA2676609A1 (en) 2007-01-26 2008-07-31 Washington University Methods and compositions for treating neuropathies
TW200918542A (en) 2007-06-20 2009-05-01 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
TW200916472A (en) 2007-06-20 2009-04-16 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
JP5425891B2 (ja) 2008-05-01 2014-02-26 サートリス ファーマシューティカルズ， インコーポレイテッド サーチュイン調節薬としてのキノリンおよび関連する類似体
EA020578B1 (ru) 2008-07-03 2014-12-30 Сертрис Фармасьютикалз, Инк. Бензимидазолы и родственные аналоги в качестве модуляторов сиртуина
EP2364698A4 (en) 2008-07-25 2011-09-14 Snu R&Db Foundation DAPSON AS A DERIVED COMPOSITION FOR CONTROLLING AGING AND / OR EXTENDING LIFE
AU2009295946B2 (en) 2008-09-29 2013-03-21 Sirtris Pharmaceuticals, Inc. Chromenone analogs as sirtuin modulators
PE20120057A1 (es) 2008-12-19 2012-02-24 Sirtris Pharmaceuticals Inc Compuestos de tiazolopiridina moduladores de sirtuina
RU2550821C2 (ru) 2009-10-29 2015-05-20 Сертрис Фармасьютикалз, Инк. Бициклические пиридины и аналоги в качестве модуляторов сиртуина
US9603862B2 (en) 2009-12-14 2017-03-28 Cornell University Activation and activators of SIRT5
WO2012094343A1 (en) 2011-01-05 2012-07-12 Trilink Biotechnologies Chemically substituted thermosensitive probes and cofactors for hot start ligation
WO2012114204A2 (en) 2011-02-15 2012-08-30 Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Tto Methods of treating mitochondrial dysfunction
WO2012125900A1 (en) 2011-03-16 2012-09-20 Enanta Pharmaceuticals, Inc. 2'-allene-substituted nucleoside derivatives
WO2013044030A1 (en) 2011-09-23 2013-03-28 Enanta Pharmaceuticals, Inc. 2'-chloroacetylenyl substituted nucleoside derivatives
RU2014120180A (ru) 2011-10-20 2015-11-27 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Замещенные бициклические аза-гетероциклы и аналоги в качестве модуляторов сиртуина
RU2014120168A (ru) 2011-10-20 2015-11-27 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Замещенные бициклические азагетероциклы и аналоги в качестве модуляторов сиртуина
KR20140077963A (ko) 2011-10-20 2014-06-24 글락소스미스클라인 엘엘씨 시르투인 조절제로서의 치환된 비시클릭 아자-헤테로사이클 및 유사체
JP6289460B2 (ja) 2012-07-16 2018-03-07 コーネル ユニヴァーシティー 難聴を治療するためのニコチンアミドリボシド
GB201313465D0 (en) * 2013-07-29 2013-09-11 Queens University Of The Belfast Methods of preparing nicotinamide riboside and derivatives thereof
EP3063163B1 (en) 2013-10-30 2022-08-10 Chromadex Inc. Nicotinamide riboside compositions for topical use in treating skin conditions

Also Published As

Publication number Publication date
MX2016016071A (es) 2017-07-11
WO2015186114A1 (en) 2015-12-10
US20170189433A1 (en) 2017-07-06
US10485814B2 (en) 2019-11-26
JP6559713B2 (ja) 2019-08-14
EP3152220A1 (en) 2017-04-12
RU2016149767A (ru) 2018-07-16
AU2015270090A1 (en) 2016-12-22
JP2017516833A (ja) 2017-06-22
KR20170008320A (ko) 2017-01-23
CN106715455A (zh) 2017-05-24
CA2951287A1 (en) 2015-12-10

Similar Documents

Publication Publication Date Title
BR112016028672A2 (pt) análogos de ribosídeo de nicotinamida e composições farmacêuticas e usos do mesmo
MX2016015997A (es) Preparacion y uso de beta-d-nicotinamida ribosido cristalina.
BR112018008783A8 (pt) terapia-alvo de câncer
BR112017002807A2 (pt) método para aprimorar a função de célula imune e método para avaliar a mulfuncionalidade de célula imune
DOP2017000094A (es) Composiciones y métodos para inhibir la expresión del gen hao1 (hidroxiácido-oxidasa 1 (glicolato-oxidasa))
BR112016024850A2 (pt) composições e métodos para modulação da expressão 3 semelhante a antiopoietina
PE20210451A1 (es) Oligonucleotidos para inducir la expresion paterna de ube3a
BR112016024494A2 (pt) análogos de peptídeo com sonda(s) de aminoácidos ramificados
BR112017023199A2 (pt) “peptídeo com atividade antiobesidade, antidiabetes e uso do mesmo”
BR112015005048A8 (pt) métodos para tratar dermatite atópica por administração de antagonista il-4r
BR112018010671A8 (pt) dispositivos e métodos de distribuição de fármaco com mudança de forma
BR112015027281A8 (pt) usos de uma população de nanocarreadores sintéticos que são fixados a imunossupressores e composição compreendendo a referida população de nanocarreadores
CO6761400A2 (es) Combinación de análogos de glucagón acilados con análogos de insulina
BR112015020078A2 (pt) jogo estendido com dispositivo de monitoramento de atividade física
UY35548A (es) Péptidos terapéuticos para el tratamiento de trastornos metabólicos.
BR112017026709A2 (pt) tratamento e diagnóstico de câncer
BR112016027871A2 (pt) composição para melhorar a memória, a função de aprendizado e/ou função cognitiva
CL2019001214A1 (es) Composición farmacéutica, métodos para tratamiento y sus usos.
BR112017000978A2 (pt) mioinositol e probióticos e usos
BR112014029346A2 (pt) sistema e método implementado por computador para a montagem de um plano de tratamento médico
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
BR112016016153A2 (pt) composições de enolase 1 (eno1) e usos das mesmas
BR112016023450A2 (pt) uso de compostos ctla4 para alcançar remissão livre de fármacos em indivíduos com artrite reumatoide precoce
CL2016001965A1 (es) Composición coadyuvante anticancerígena que contiene rip3 expresión del promotor como ingrediente activo, método para seleccionar composición coadyuvante anticancerígena para mejorar la sensibilidad de droga anticancerigena, promoviendo la expresión rip3, y metodo para seguimiento de sensibilidad; medicamento contra el cáncer
BR112019011802A2 (pt) composições nutricionais contendo butirato e/ou lactoferrina e usos das mesmas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07H 19/048 , A61K 31/7064 , A61P 3/10 , A61P 17/00 , A61Q 17/00

Ipc: A61K 31/706 (2006.01), A61K 31/7064 (2006.01), A61

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements